Nomura: Sinobiopharma partners with Boehringer Ingelheim again, with near-term payments of 358 million dollars

Which assets and rights are covered by the partnership?

On 4 November, Sinobiopharma announced another partnership with Boehringer Ingelheim involving six preclinical assets, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs).
Sinobiopharma will lead early development through completion of Phase I clinical trials. Boehringer Ingelheim has options to acquire global rights to two assets and rights outside Greater China to the other four.

The deal includes 358 million dollars in upfront and near-term payments, plus potential option fees and research, development and commercialization milestone payments, for a combined total of up to 7 billion dollars. It also includes tiered sales royalties.
By Nomura’s comparison, the upfront and near-term payments equal approximately 23% of the company’s combined operating profit for the second half of 2025 and the first half of 2026. The bank therefore expects the deal to significantly benefit financial performance in fiscal years 2026 and 2027.
The 7 billion-dollar figure is the total including potential subsequent payments. Whether the assets advance to later stages and the related options are exercised and milestones achieved will affect the final amount received.

This is the parties’ second oncology partnership and Sinobiopharma’s third out-licensing deal so far in 2026. Nomura believes the successive deals demonstrate the company’s research and development capabilities and out-licensing prospects, and are also supportive of market sentiment.
Nomura maintains its buy rating and target price of 8.67 Hong Kong dollars. Its discounted cash flow model uses a weighted average cost of capital of 9.5% and a perpetual growth rate of 3%. The bank’s listed downside risks include weaker-than-expected sales and failure to secure more out-licensing deals.